- February 26, 2021
CarthroniX has entered into a collaboration with SMC Labs, Japan to explore the therapeutic potential of novel systemic gp130 modulators in animal models of chronic inflammatory and fibrotic disorders. SMC Labs is one of the leading CRO’s in this area specializing in pre-clinical models for drug development.
SMC Labs is a pre-clinical CRO development through focused fibrosis and inflammatory expertise. SMC Labs supported over 700 pharmaceutical companies, bio-ventures and academics from over 29 countries with their cutting-edge research and pharmacology studies using their mouse models. In particular, NASH-HCC model (STAM model) is a mouse model with high clinical correlation – 15 compounds tested in the model having progressed to clinical trials. https://smccro-lab.com/